Martínez-Gómez, XavierCurran, AdrianCampins Martí, MagdaAlemany i Vilches, LaiaRodrigo-Pendás, José ÁngelBorruel, NataliaCastellsagué, XavierDíaz-de-Heredia, CristinaMoraga Llop, Fernando A.Pino Saladrigues, Marta delTorné Bladé, Aureli2020-06-102020-06-102019-02-241025-496Xhttps://hdl.handle.net/2445/165093Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. Aim: To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. Methods: We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results: A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9-26 years; men who have sex with men aged 9-26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9-26 years; and patients diagnosed with recurrent respiratory papillomatosis. Conclusions: Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.14 p.application/pdfengcc-by (c) Martínez-Gómez, Xavier et al., 2019http://creativecommons.org/licenses/by/3.0/esVacuna del papil·lomavirusImmunogenèticaPapillomavirus vaccinesImmunogeneticsinfo:eu-repo/semantics/article6956432020-06-10info:eu-repo/semantics/openAccess30782268